Trials & Filings

Cellectar Receives FTD for Diffuse Large B-Cell Lymphoma Treatment

Drug conjugate, CL131, delivers cytotoxic radiation directly and selectively to cancer cells

Cellectar Biosciences, Inc. was granted Fast Track Designation by the FDA for CLR 131 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).    CLR 131 is the company’s small-molecule, cancer-targeting radiotherapeutic Phospholipid Drug Conjugate™ (PDC™) designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. It is currently being evaluated in Cellectar’s ongoing Phase 2 CLOVER-1 clinical study in patients with relapsed or refractory se...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters